Physician profile
David M Baker
NPI 1063464279
$3,450.01
in general payments reported to CMS, 2019-2025
27 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $285 · 2021: $231 · 2022: $285 · 2023: $750 · 2024: $980 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,223.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $638.19 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $398.76 | 2023-2024 | Watchman Access System, Rhythmia Mapping System, Lux-Dx Insertable Cardiac Monitor |
| Janssen Pharmaceuticals, INC | $349.56 | 2019-2022 | |
| Abbott Laboratories | $273.28 | 2019-2025 | Aveir, Gallant |
| E.R. Squibb & Sons, L.L.C. | $220.05 | 2019-2025 | Camzyos |
| Medtronic, INC. | $209.75 | 2024 | Corevalve Evolut R |
| Scpharmaceuticals INC. | $181.51 | 2023 | |
| Pfizer INC. | $176.35 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $173.84 | 2019-2025 | |
| Edwards Lifesciences Corporation | $142.49 | 2021-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals Lp | $103.44 | 2019-2023 | Andexxa |
| Cvrx, INC. | $100.75 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.47 | 2019-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $67.43 | 2019 | |
| Merck Sharp & Dohme LLC | $41.45 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $38.49 | 2023-2024 | Opsumit, Uptravi |
| Amgen INC. | $34.82 | 2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.47 | 2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $23.79 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $22.40 | 2024 | |
| Esperion Therapeutics, INC. | $20.99 | 2024 | Nexletol |
| Novo Nordisk INC | $20.20 | 2024 | Wegovy |
| Tactile Systems Technology INC | $18.95 | 2020 | |
| Philips North America LLC | $18.67 | 2020 | |
| Atricure, INC. | $17.26 | 2025 | Atriclip Laa Exclusion System |
| Medtronic Vascular, INC. | $14.45 | 2019 | |
| Amarin Pharma, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.